Article
Gilead Sciences' remdesivir cuts COVID-19 death risk in patients on low-flow oxygen
Rating:
0.0
Views:
126
Likes:
1
Library:
1
Gilead Sciences' remdesivir has been a crucial treatment for COVID-19 for months, but new data from a “gold standard” trial give a clearer picture of the med's benefit. The drug improved recovery times, reduced chances of patients progressing to more severe stages of illness and significantly cut the risk of death in a subset of patients.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value